141TiPAZD9291, A THIRD GENERATION EGFR INHIBITOR, VERSUS GEFITINIB OR ERLOTINIB IN TREATMENT-NAïVE PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBOURING AN EGFR-TKI-SENSITISING MUTATION (EGFRM): A RANDOMISED, PHASE III STUDY (FLAURA)


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles